SLOW RECOVERY FOR PHYSIO-CONTROL PRODUCTS GOOD FOR ZOLL

The fallout of the recent removal from the U.S. market of external defibrillators manufactured by Medtronic's Physio-Control unit is still unpredictable, according to RBC Capital Markets analyst Phil Nalbone.

"It has been over a month since Physio suspended U.S. shipments, and we believe the fact that management will still not provide details is positive" for rival firm Zoll Medical, which is profiting from its largest competitor being out of the market, Nalbone said in a Feb. 21 research note.

Zoll should capture $16.2 million in the professional defibrillator market and an additional $5.6 million in sales of automated external defibrillators, Nalbone added.